Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.
Melanoma Res
; 34(3): 280-282, 2024 06 01.
Article
em En
| MEDLINE
| ID: mdl-38602773
ABSTRACT
Although generally well tolerated compared with chemotherapy, molecular targeted therapy used in metastatic melanoma may be associated with life-threatening toxicity. We report the case of a patient with metastatic melanoma treated by dabrafenib plus trametinib who developed intracranial hemorrhage. Physicians should be aware of this rare but life-threatening adverse event of B-rapidly accelerated fibrosarcoma (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors. However, they should be also careful about the bleeding origin, which can prove to be a new onset of melanoma metastasis or anticoagulation overdose, or even an uncontrolled arterial hypertension.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Hemorragias Intracranianas
/
Melanoma
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article